Advertisement

Definition, Einteilung, Chemie

  • H. Herrschaft

Zusammenfassung

Unter Antidementiva werden am ZNS wirkende Arzneimittel verstanden, die höhere intregrative noetische Funktionen, wie Gedächtnis, Denken, Aufmerksamkeit, Auffassung, Konzentrations- und Lernfähigkeit, Orientierung und Vigilanz verbessern. Diese Begriffsbestimmung orientiert sich an der klinischen Wirksamkeit. Ein einheitlicher pharmakologischer Wirkungsmechanismus ist nicht bekannt. Synonyma für Antidementiva in der internationalen Literatur sind: „cognition enhancers, cerebro-active drugs, Antidementia, cerebrale Antihypoxidotika, Neurodynamika und Geriatrika“.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. ADENA 1: Data on File. SDZ ENA 713 in mild to moderate senile dementia of the Alzheimer’s type. Study report IND 35-774. Summary of the human pharmacokinetics and bioavailability of ENA 713. Novartis Pharmaceuticals CorporationGoogle Scholar
  2. ADENA 2: Data on File. Summary of product characteristics. January 1998. Novartis Pharmaceuticals CorporationGoogle Scholar
  3. ADENA 3: Data on File. Draft labeling. April 1997, NDA 20-823. Novartis Pharmaceuticals CorporationGoogle Scholar
  4. ADENA 4: Data on File. Integrated summary of effectiveness. 15 April 1997. Novartis Pharmaceuticals CorporationGoogle Scholar
  5. ADENA 5: Anand R, Gharabawi G. The ADENA programme: International coordinated phase III development of a second generation acetylcholinesterase inhibitor (SDZ ENA-713). Poster presentationGoogle Scholar
  6. ADENA 6: Data on File. Integrated clinical and statistical study report. Ena B303-E-00. 28 February 1997, Novartis Pharmaceuticals CorporationGoogle Scholar
  7. Albizatti MG, Bassi S, Sbacchi M, Frattola L (1984) Clinical effects of cyclospasmol in patients affected by chronic cerebrovascular disorders. Br J Clin Pract 38 [Suppl]: 69–73Google Scholar
  8. Anand R, Gharabawi G (1996) Clinical development of Exelon (ENA-713): The ADENA programme. J Drug Dev Clin Pract 8: 9–14Google Scholar
  9. Battaglia A, Annoni K, Pamparana F et al. (1995) Nicergoline in the long-term treatment of mild or moderate senile dementia. A multicenter, double-blind randomized, placebo-controlled trial (abstract). VIIth ECNP Congress, September 1995, Venice, p 383Google Scholar
  10. Battaglia A, Bruni G, Ardia A et al. (1989) Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebo-controlled study. J Am Geriatr Soc 19: 292–302Google Scholar
  11. Bjürwill BB (1985) Behandlung des hirnorganischen Psychosyndroms bei Alterspatienten mit Piracetam. Stockholm, Blackebergs Hospital. UCB-Chemie, KölnGoogle Scholar
  12. Black RS, Barclay LL, Nolan KA, Thaler HT, Hardiman ST, Blass JP (1992) Pentoxifylline in cerebrovascular dementia. J Am Geriatr Soc 40: 237–244PubMedGoogle Scholar
  13. Blume JK, Rühlmann U, De La Haye R, Rettig H (1990) Vascular bedingte Hirnleistungsstörungen im Alter. Langzeittherapie mit Pentoxifyllin und psychologischem Ferntraining. Fortschr Med 108: 638–642PubMedGoogle Scholar
  14. Brückner GW, Jansen, W (1979) über den Einfluß einer 10 wöchigen Therapie mit Nimodipin auf Symptomatik und cerebrale Leistungsfähigkeit von Alterspatienten mit cerebrovaskulärer Insuffizienz. Bayer AG, LeverkusenGoogle Scholar
  15. Campi N, Todeschini GP, Scarzella L (1990) Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 12: 306–314PubMedGoogle Scholar
  16. Corey-Bloom J, Anand R, Veach J für die ENA BG 352-STUDIENGRUPPE (1998) Randomisierte Studie zur Prüfung der Wirksamkeit und Sicherheit von ENA 713 (Rivastigmintartrat), einem neuen Azetylcholinesterasehemmer, bei Patienten mit leichter bis mittelschwerer Demenz vom Alzheimer Typ. Int J Geriatr Psychopharmacol 1: 55–65Google Scholar
  17. CPMP Working Party on Efficacy of Medicinal Products (1992) Note for guidance. Antidementia medicinal products. Commission of the European Communities Brussels, III/3705-91-EN, Draft 5Google Scholar
  18. Coper H, Hermann WM (1988) Psychostimulants, analgetics, nootropics: an attempt to differentiate and assess drugs designed for the treatment of impaired brain functions. Pharmacopsychiatry 21: 211–217PubMedCrossRefGoogle Scholar
  19. Croisile B, Trillet M, Fondarai J, Laurant B, Maugiere F, Billardon M (1993) Long-term and high-dose piracetam treatment of Alzheimer’s disease. Neurology 43: 301–305PubMedCrossRefGoogle Scholar
  20. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woodson R, Gracon SI, Drethman DA, Schneider LS, Whitehouse RJ, Hoover TM, Morris JC, Kawas CH, Knopmann DS, Earl NL, Kumar V, Doody RS (1989) A double-blind placebo-controlled multicenter study of tacrin for Alzheimer’s disease. N Engl J Med 327: 1253–1259CrossRefGoogle Scholar
  21. Ditzler K (1991) Efficacy and tolerability of Memantine in patients with dementia syndroms. A double-blind, placebo-controlled trial. Arzneimittelforschung 41: 773–780PubMedGoogle Scholar
  22. Dominguez D, de Cayafera CL, Gomensore J, Aparicio NJ (1977) Modification of psychometric, practical and intellectual parameters in patients with diffuse cerebrovascular insufficiency during prolonged treatment with pentoxifylline: a double-blind, placebo controlled trial. Pharmatherapeutica 1: 498–506Google Scholar
  23. Eagger SA, Levy R, Sahakian BJ (1991) Tacrine in Alzheimer’s disease. Lancet 337: 989–992PubMedCrossRefGoogle Scholar
  24. Empfehlungen zum Wirksamkeitsnachweis von Nootropica im Indikationsbereich Demenz (Phase III) (1991) Gemeinsames Papier der das Bundesgesundheitsamt beratenden Zulassungskommission für neue Stoffe (Kommission A) und der Auf bereitungskommission „Neurologie, Psychiatrie“ (Kommission B 3). Bundesgesundheitsblatt 7: 342–350Google Scholar
  25. European Pentoxifylline Multi-Infarct Dementia Study (EPMID) (1996) Eur Neurol 36: 315–321CrossRefGoogle Scholar
  26. Fanchamps A (1979) Controlled studies with dihydroergotoxine in senile cerebral insufficiency. In: Nandy K (ed) Geriatric psychopharmacolocy. Elsevier North-Holland, New York, pp 195–212Google Scholar
  27. Fanchamps A (1983) In: Spano PF, Trabucchi M (eds) Aging brain and ergot alkaloids. Raven Press, New York, pp 311–322 (Aging vol 23)Google Scholar
  28. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolon-Ureno J (1992) A controlled trial of tacrine in Alzheimer’s disease. JAMA 268: 253–259CrossRefGoogle Scholar
  29. FDA Antidementia Drug Assessment Symposium, Rockville Md (1989) Department of Health and Human Services, Public Health Service. Food and Drug Administration, Peripheral and Central Nervous System Drugs Advisory Panel. Antidementia Drug Assessment Symposium, vol II. Miller Reporting Co Inc, Washington DCGoogle Scholar
  30. Finali G, Piccinelli M, Oliani C, Piccinin GL (1991) L-Deprenyl therapy improves verbal memory in amnesic Alzheimer patients. Clin Neuropharmacol 14: 523–536PubMedCrossRefGoogle Scholar
  31. Fleischmann UM (1990) Wirkeffekte nootroper Substanzen bei Alterspatienten — eine Sekundäranalyse am Beispiel von Piracetam. Z Gerant Psychiatr 4: 285–304Google Scholar
  32. Fröstl W, Maitre L (1989) The families of cognition enhancers. Pharmacopsychiatry 22: 54–100PubMedCrossRefGoogle Scholar
  33. Gaab MR, Haubitz I, Brawanski A, Czech TH, Kom A (1985) Acute effects of nimodipine on the cerebral blood flow and intracranial pressure. Neurochirurgia 28: 93–99PubMedGoogle Scholar
  34. Gauthier S, Rossor M, Hecker J, Burns A et al. (1998) Results from a multinational Phase III clinical trial of donepezil in Alzheimer’s disease. Presented at 5th Int Geneva/Springfield Symposium on Advances in Alzheimer Therapy, April 15–18, 1998 (Poster 24B)Google Scholar
  35. Giurgea CE (1972) Vers une pharmocologie de l’activité integrative au cerveau. Tentalive du concept neurotrope en psychopharmacologie. Act Pharmacol 25: 115–157Google Scholar
  36. Goncalves N (1979) Pyritinol bei ambulanten geriatrischen Patienten: Eine placebo-kontrol-lierte Verbundstudie. Med Welt 30: 494–498PubMedGoogle Scholar
  37. Görtelmeyer R, Erbler H (1993) Therapie leichter bis mittelschwerer Hirnleistungsstörungen bei Patienten mit dementiellem Syndrom mit Memantine. Arzneimittelforschung 42: 904–913Google Scholar
  38. Halama P, Bartsch G, Meng G (1988) Hirnleistungsstörungen vaskulärer Genese. Fortschr Med 106: 408–412PubMedGoogle Scholar
  39. Hardy B, Lenisa S (1992) Selegiline (L-deprenyl) for Alzheimer’s dementia. On Continuing Practice 19: 5–10Google Scholar
  40. Hartmann A, Alberti E, Lange D (1979) Effect of pentoxifylline on regional CBF and CBV in dementia. Acta Neurol Scand 60 [Suppl 72]: 624–625Google Scholar
  41. Harwart D (1979) The treatment of chronic cerebrovascular insufficiency. A double-blind study with pentoxifylline (Trental 400). Curr Med Res Opin 6: 73–84PubMedCrossRefGoogle Scholar
  42. Harwart H, Biastock E (1982) Kontrollierte Doppelblindstudie mit Nimodipin bei Patienten mit Hirnleistungsstörungen im Alter. Bayer, Leverkusen (unveröffentlicht)Google Scholar
  43. Hebenstreit GF (1986) Die Wirkung eines Aminosäure-Peptid-Extraktes bei zerebralen Funktionsstörungen in der Gerontopsychiatrie. Neuropsychiatrie 1: 38–44Google Scholar
  44. Heiss W-D, Hebold T, Klinkhammer P, Ziffling P, Szeilies B, Pawlik G, Herholz K (1988) Effect of piracetam on cerebral glucose metabolism in Alzheimer’s disease as measured by positron emission tomography. J Cereb Blood Flow Metabol 8: 613–617CrossRefGoogle Scholar
  45. Heiss WD, Kessler J, Adams R, Szelies B, Maurer K, Grond M, Klinkhammer P, Fink G, Herholz K (1990) PET for differential diagnosis and for treatment control in dementias. In: Gerstenbrand F, Grcevic N (eds) Advances in clinical neuroimaging. Elsevier, Amsterdam New York Oxford, pp 11–24Google Scholar
  46. Hermann WM, Kern I (1987) Nootropica: Wirkung und Wirksamkeit. Eine überlegung am Beispiel einer Phase III-Prüfung mit Piracetam. Nervenarzt 58: 358–364Google Scholar
  47. Hermann WM, Apecechea M, Gaede K (1992) Multicenter double-blind randomized clinical trial to assess the efficacy and tolerability of nicergoline 30 mg bid vs placebo in geriatric outpatients suffering from multi-infarct dementia. Farmitalia Carlo Erba Clinical Trial Report no 758Google Scholar
  48. Hermann WM, Kern U, Röhmel J (1986) On the effects of pyritinol on functional deficits of patients with organic mental disorders. Pharmacopsychiatry 19: 378–385CrossRefGoogle Scholar
  49. Herrschaft H (1978) Die Wirkung von Pyritinol auf die Gehirndurchblutung des Menschen. Münch Med Wochenschr 120: 1263–1268Google Scholar
  50. Herrschaft H (1997) Der Stellenwert der Nootropika bei der Behandlung der Demenz vom Alzheimer-Typ. Psycho 23: 111–125Google Scholar
  51. Hoyer S, Oesterreich K, Stoll K-D (1977) Effects of pyritinol-HCI on blood flow and oxidative metabolism of the brain in patients with dementia. Arzneimittelforschung 27: 671–674PubMedGoogle Scholar
  52. Hoyer S, Krüger G, Oesterreich K, Weinhardt F (1976) Effects of drugs on cerebral blood flow and oxidative metabolism in patients with dementia. In: Cerebrovascular disease. Proc, 8th Int Salzburg Conference, September 23–25. Excerpta Medica, Amsterdam Oxford, pp 25–27 (Excerpta Medica Int Congress Series 425)Google Scholar
  53. Ihl R, Dierks T, Martin E, Fröhlich L, Maurer K (1992) Ginkgo biloba Extrakt. EGb 761 bei der Demenz vom Alzheimer Typ. Vortrag Regensburg, 15. Donau-Symposium für PsychiatrieGoogle Scholar
  54. Kanowski S, Fischhof P, Hiersemenzel R, Röhmel J, Kern U (1988) Wirksamkeitsnachweis von Nootropika am Beispiel von Nimodipin–ein Beitrag zur Entwicklung geeigneter klinischer Prüf modelle. Z Gerontopsychol Psychiatr 1: 35–44Google Scholar
  55. Kanowski S, Herrmann WH, Stephan K, Wierich W, Hörr R (1996) Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer Type or multiinfarct dementia. Pharmacopsychiat 29: 47–56CrossRefGoogle Scholar
  56. Kapoula O, Lehrl S, Fischer B, Wedekind W, Woelk H, Burkhard G (1994) Plazebokontrollierte Doppelblindstudie zur Prüfung der therapeutischen Wirksamkeit von Cyclandelat bei ambulanten Patienten mit vaskulär bedingten Hirnleistungsstörungen im Alter. 3 M Medica (Intern Report)Google Scholar
  57. Kaye WH, Sitaram H, Weingartner H, Eber MH, Smallberg S, Gillin JC (1982) Modest facilitation of memory in dementia with combined lecithin and anticholinesterase treatment. Biol Psychiatry 17: 275, 280PubMedGoogle Scholar
  58. Kittner B (1996) Propentofylline. Efficacy demonstrated in both vascular and Alzheimer’s type dementia. IV. Internat Nice/Springfield Symposium on Advances in Alzheimer Therapy, Nice, France, April 1996Google Scholar
  59. Knapp MJ, Knopman DS, Salomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trial of highdose tacrine in patients with Alzheimer’s disease. JAMA 271: 985–991PubMedCrossRefGoogle Scholar
  60. Knezevic S, Mubrin Z, Spilich G, Vucinic G, Wannemacher W (1990) Long termin treatment of SDAT patients with pyritinol. In: Maurer K, Riederer P, Beckmann H (eds) Alzheimer’s disease. Epidemiology, neuropathology, neurochemistry and clinics. Springer, Wien New York, pp 565–574Google Scholar
  61. Kofler B, Erhart C, Erhart G, Harrer G (1990) A multidimensional approach in testing nootropic drug effects. (Cerebrolysin). Arch Gerontol Geriatr 10: 129–140PubMedCrossRefGoogle Scholar
  62. Le Bars PL, Katz MM, Berman N, Freedman AM, Schatzberg AP (1997) Placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. JAMA 278: 1327–1332PubMedCrossRefGoogle Scholar
  63. Lehrl S, Blah S, Kapoula O (1995) Auswirkungen neuer Aspekte der Kontrollen von Behandlungsmaßnahmen bei Demenzen im Alter auf Therapieentscheidungen und Meta-Analyseergebnisse mit einer beispielhaften Anwendung auf Cyclandelatstudien. Geriatr Forsch 5: 89–101Google Scholar
  64. Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, Marcone A, Smirne S (1991) Effects of a MOA-B inhibitor in the treatment of Alzheimer’s disease. Eur Neurol 31: 100–107PubMedCrossRefGoogle Scholar
  65. Menazzi D, Montenegro R, Castro JM (1985) Nimodipine in the treatment of chronic cerebrovascular insufficiency. In: Betz E, Deck K, Hoffmeister F (eds) Nimodipine. Pharmacological and clinical properties. Proceedings, 1st International Symposium, München, February 1984. Schattauer, Stuttgart New York, pp 333–344Google Scholar
  66. Monteverde A, Gnemmi P, Rossi R, Monteverde A, Finali GC (1990) Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 12: 315–322PubMedGoogle Scholar
  67. Mubrin Z, Knesevic S, Spillich G, Risberg J, Gubarev N, Wannenmacher W, Vucinic G (1989) Normalization of rCBF pattern in senile dementia of Alzheimer’s type. Psychiatry Res 29: 303–306PubMedCrossRefGoogle Scholar
  68. Nagasawa H, Kogurt K, Kawashima T et al. (1989) Influence of Hydergine on brain cell metabolism as demonstrated by PET. In: Carlson A, Kanowski S, Allan H, Spiegel R (eds) Cerebral insufficiency. Trends in research and treatment, vol 1–4. Parthenon Publishing Group, Carnforth (UK), and Park Ridge (USA) vol 3, pp 169–178Google Scholar
  69. Nicergoline Cooperative Study Group (1990) A double-blind randomized study of two ergot dérivates in mild to moderate dementia. Curr Ther Res 48: 597–612Google Scholar
  70. Oswald WD, Oswald B (1988) Zur Replikation von Behandlungseffekten bei Patienten mit hirnorganischen Psychosyndromen im Multizenter-Modell als Indikator für klinische Wirksamkeit. Eine plazebo-kontrollierte Doppelblindstudie mit Pyritinol. Gerontopsych Gerontopsychiatr 1: 223–241Google Scholar
  71. Oswald WD, Matejcek M, Lukaschek K (1982) über die Relevanz psychometrisch operationalisierter Therapie-Effekte bei der Behandlung altersbedingter Insuffizienzerscheinungen des Gehirns als Beispiel des Nürnberger-Alters-Inventars. Arzneimittelforschung 32: 584–590PubMedGoogle Scholar
  72. Ott E (1988) Behandlungsergebnisse mit Piracetam bei der Multi-Infarkt-Demenz. In: Helmchen H (Hrsg) Wirkungen und Wirksamkeit von Nootropika. Springer, Berlin Heidelberg New York Tokyo, S 162–168CrossRefGoogle Scholar
  73. Pantev M, Ritter R, Görtelmeyer R (1993) Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Z Gerontopsychol Psychiatr 6: 103–117Google Scholar
  74. Parnetti L, Ciuffetti G, Mercuri M et al. (1986) The role of haemorheological factors in the aging brain: long-term therapy with pentoxifylline (Trental 400) in elderly patients with initial mental deterioration. Pharmatherapeutica 4: 617–627PubMedGoogle Scholar
  75. Passero S, Nardini M, Battistini M (1981) Effect of pentoxifylline on cerebral blood flow in patients with chronic cerebrovascular disease. J Int Med Res 9: 211–214PubMedGoogle Scholar
  76. Perez GM (1981) Evaluation of the clinical efficacy of piracetam in the deterioration of the intellectual functions of a geriatric population: a double-blind study. Second International Symposium on Nootropic Drugs, Mexico. UCB-Publ, pp 53–62Google Scholar
  77. Reeve FBA, Evans CA (1994) A multicentre, multinational, double-blind, placebo controlled study of the efficacy and tolerability of nicergoline in patients suffering from mild to moderate senile dementia. Pharmacia Internal Report no. 6714: 663Google Scholar
  78. Risberg J, Knesevic S (1990) Contribution of 133-Xe rCBF to diagnosis and treatment of dementia. In: Gerstenbrand F, Grcevic N, Aichner F (eds) Advances in clinical neuroimaging. Elsevier, Amsterdam New York Oxford, pp 35–47Google Scholar
  79. Rogers SL, Friedhoff L (1998) Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 8: 67–75PubMedCrossRefGoogle Scholar
  80. Rogers SL, Friedhoff LT, The Donepezil Study Group (1996) The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 7: 293–303PubMedGoogle Scholar
  81. Rogers SL, Doody RS, Mohs RC, Friedhoff LT et al. (1998) Donepezil improves cognition and global function in Alzheimer disease. Arch Intern Med 158: 1021–1031PubMedCrossRefGoogle Scholar
  82. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT et al. (1998) A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50: 136–145PubMedCrossRefGoogle Scholar
  83. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartmann R, Gharabawi M on behalf of the B 303 Exelon Study Group (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: International randomized controlled trial. BMJ 18: 633–648CrossRefGoogle Scholar
  84. Rössner M, Taeubner K (1989) Evaluation of efficacy and safety of protenofylline (HWA 285) in the treatment of progressive degenerative dementia (PDD) and multiinfarct dementia (MID). Internal Report, Hoechst AG, WiesbadenGoogle Scholar
  85. Rössner M, Reiker J, Deutsch H (1989) Study of efficacy and safety of HWA 285 in the treatment of senile dementia of Alzheimer type (SDAT) and multiinfarct dementia. Internal Report, Hoechst AG, WiesbadenGoogle Scholar
  86. Rüther E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the petidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiat 27: 32–40CrossRefGoogle Scholar
  87. Saletu B, Möller HJ, Grünberger J, Deutsch H, Rössner M (1990) Propentofylline in adult-onset cognitive disorders: double-blind placebo-controlled, clinical, psychometric and brain mapping studies. Neuropsychobiology 24: 173–184PubMedCrossRefGoogle Scholar
  88. Saletu B, Paulus E, Linzmayer E, Anderer P et al. (1995) Nicergoline in seline dementia of Alzheimer type and multi-infarct dementia. A double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 117: 385–395PubMedCrossRefGoogle Scholar
  89. Schneider LS, Olin JT, Pawluczyk S (1993) A double-blind crossover pilot study of L-deprenyl (selegiline) combined with Cholinesterase inhibitor in Alzheimer’s disease. Am J Psychiatry 150: 321–323PubMedGoogle Scholar
  90. Skondia V (1979) Criteria for clinical development and classification of nootropic drugs. Clin Ther 2/5: 316–332Google Scholar
  91. Singer JM, Harnot HB, Patin JR (1985) Differential patient response to ergoloid mesylates according to current etiopathic notions of dementia. In: Gaitz CM, Samorajski T (eds) Aging 2000. Our health care destiny. Springer, New York, pp 405–420 (Biochemical Issues, vol 1)CrossRefGoogle Scholar
  92. Suchanek-Fröhlich H, Wunderlich E (1986) über die Wirksamkeit eines Aminosäure-Peptid-Extraktes. Randomisierte Doppelblind-Vergleichsstudie. Neuropsychiatrie 1: 45–48Google Scholar
  93. Weibel L (1981) Piracetam v/s Pyritinol in the treatment of psychoorganic syndrome patients. Second International Symposium of Nootropic Drugs Mexico. UCB-Publ, pp 66–70Google Scholar
  94. Weitbrecht W-U, Jansen W (1986) Primär degenerative Demenz: Therapie mit Ginkgobiloba-Extrakt. Placebokontrollierte Doppelblind-und Vergleichsstudie (Therapy with ginkgo biloba extract. Placebo-controlled double-blind and comparative study). Fortschr Med 104: 199–202PubMedGoogle Scholar
  95. Wesnes K, Simmons D, Rook M, Simpson P (1987) A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. Hum Psychopharmacol 2: 159–169CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • H. Herrschaft

There are no affiliations available

Personalised recommendations